How many insider trades does FilingIQ track for RNA?

FilingIQ tracks 347 Form 4 insider transactions for RNA (Atrium Therapeutics, Inc.), covering filings from Jun 16, 2020 onwards. 17 of those were filed in the last 90 days.

Are RNA insiders net buyers or net sellers?

Across the full Form 4 history for RNA, 3 transactions (1%) were open-market purchases and 160 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RNA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RNA in?

Atrium Therapeutics, Inc. (RNA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.30B.

RNA insider trading

NasdaqGS Healthcare

Atrium Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

347

Last 90 days

Buys / sells

1% / 46%

Market cap

$2.30B

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known as Bryce Therapeutics, Inc. Atrium Therapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. operates as a subsidiary of Avidity Biosciences, Inc.

RNA insider activity at a glance

FilingIQ has scored 347 insider transactions for RNA since Jun 16, 2020. The most recent filing in our index is dated Apr 20, 2026.

Across the full history, 3 open-market purchases and 160 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RNA insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RNA trades on FilingIQ Raw filings on SEC EDGAR

Latest RNA Form 4 filings

MacLean Michael F Chief Financial Officer

S Aug 6, 2025

Boyce Sarah President and CEO

S Mar 20, 2025

Boyce Sarah President and CEO

S Dec 18, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding RNA

Avoro Capital Advisors LLC

$393.47M · 3.9% of AUM

Casdin Capital, LLC

$85.17M · 6.5% of AUM

COWEN AND COMPANY, LLC

$50.94M · 3.3% of AUM

Siren, L.L.C.

$32.79M · 1.8% of AUM

Frazier Life Sciences Management, L.P.

$11.10M · 0.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for RNA?: FilingIQ tracks 347 Form 4 insider transactions for RNA (Atrium Therapeutics, Inc.), covering filings from Jun 16, 2020 onwards. 17 of those were filed in the last 90 days.
Are RNA insiders net buyers or net sellers?: Across the full Form 4 history for RNA, 3 transactions (1%) were open-market purchases and 160 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RNA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RNA in?: Atrium Therapeutics, Inc. (RNA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.30B.

Methodology & sources

Every RNA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.